The following post is by HIVMA Executive Director Andrea Weddle, reporting from the International AIDS Conference in Vienna. “There’s no separate science for the rich and poor. The research applies to both,” said Dr. Peter Mugyenyi when asked whether “when to start to HIV treatment” was a real question for Uganda and countries in sub-Saharan […]
Vienna — “Slow, timid, and uncoordinated.” Those were the words Tony Harries, Senior Adviser to the International Union Against Tuberculosis and Lung Disease, used to describe the response to deadly HIV/TB co-infection, with its 40 percent mortality. Harries opened the session of TB and HV Management in High-Prevalence Settings Wednesday morning at the 18th International […]
During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, […]
HIV
The following is a guest post by Mitchell Warren of AVAC This year’s annual HIV Vaccine Awareness Day arrives Saturday at a promising and also perilous […]
Tuberculosis
In sub-Saharan Africa where the odds of dying within a year of starting treatment for HIV can still hover close to one-in-10, diagnosing and treating TB […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
The following is a guest post by Heather B. Davis, MPH, and Emily A. Bobrow, PhD, MPH, of MEASURE Evaluation Who has a strategic interest in […]